DK1865924T3 - Method of treating prostate diseases based on local administration of active substances - Google Patents

Method of treating prostate diseases based on local administration of active substances Download PDF

Info

Publication number
DK1865924T3
DK1865924T3 DK06724133.1T DK06724133T DK1865924T3 DK 1865924 T3 DK1865924 T3 DK 1865924T3 DK 06724133 T DK06724133 T DK 06724133T DK 1865924 T3 DK1865924 T3 DK 1865924T3
Authority
DK
Denmark
Prior art keywords
prostate
kit
drug
controlled release
component
Prior art date
Application number
DK06724133.1T
Other languages
Danish (da)
English (en)
Inventor
Hans Lennernäs
Bo Lennernäs
Jonas Hugosson
Niklas Axen
Original Assignee
Lidds Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lidds Ab filed Critical Lidds Ab
Application granted granted Critical
Publication of DK1865924T3 publication Critical patent/DK1865924T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Botany (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK06724133.1T 2005-03-31 2006-03-31 Method of treating prostate diseases based on local administration of active substances DK1865924T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200500452 2005-03-31
PCT/EP2006/003194 WO2006103112A2 (en) 2005-03-31 2006-03-31 Method for treating prostate diseases based on local delivery of active substances

Publications (1)

Publication Number Publication Date
DK1865924T3 true DK1865924T3 (en) 2016-02-29

Family

ID=35044589

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06724133.1T DK1865924T3 (en) 2005-03-31 2006-03-31 Method of treating prostate diseases based on local administration of active substances

Country Status (17)

Country Link
US (1) US8936809B2 (cg-RX-API-DMAC7.html)
EP (1) EP1865924B1 (cg-RX-API-DMAC7.html)
JP (2) JP5635231B2 (cg-RX-API-DMAC7.html)
KR (2) KR20140014294A (cg-RX-API-DMAC7.html)
CN (1) CN101160116B (cg-RX-API-DMAC7.html)
AU (1) AU2006228675B2 (cg-RX-API-DMAC7.html)
CA (1) CA2602776C (cg-RX-API-DMAC7.html)
DK (1) DK1865924T3 (cg-RX-API-DMAC7.html)
ES (1) ES2557988T3 (cg-RX-API-DMAC7.html)
HU (1) HUE026158T2 (cg-RX-API-DMAC7.html)
IL (1) IL185690A0 (cg-RX-API-DMAC7.html)
MX (1) MX2007011908A (cg-RX-API-DMAC7.html)
NO (1) NO338679B1 (cg-RX-API-DMAC7.html)
PL (1) PL1865924T3 (cg-RX-API-DMAC7.html)
RU (1) RU2404747C2 (cg-RX-API-DMAC7.html)
WO (1) WO2006103112A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200708066B (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140014294A (ko) * 2005-03-31 2014-02-05 리드스 에이비 유효 물질의 국소 전달을 기본으로 하는 전립선 질병의 치료 방법
MX2011005243A (es) * 2008-11-27 2011-08-08 Lidds Ab Uso de carboximetilcelulosa para controlar la eyectabilidad y el tiempo de solidificacion de las composiciones que comprenden una o mas ceramicas biorreabsorbibles.
AU2012240131B2 (en) * 2011-04-05 2017-07-20 Edge Therapeutics Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow
RU2519407C2 (ru) * 2011-09-21 2014-06-10 Виктор Павлович Горелов Способ трансуретральной резекции предстательной железы, предшествующий брахитерапии рака простаты
GB201318858D0 (en) * 2013-10-25 2013-12-11 Glaxosmithkline Biolog Sa Calcium fluoride compositions
GB201318862D0 (en) * 2013-10-25 2013-12-11 Glaxosmithkline Biolog Sa Calcium fluoride compositions
WO2016028774A1 (en) 2014-08-19 2016-02-25 The Regents Of The University Of California Implants for localized drug delivery and methods of use thereof
JP6758325B2 (ja) 2015-06-04 2020-09-23 クリティテック・インコーポレイテッド タキサン粒子およびその使用
CN114767860A (zh) 2016-04-04 2022-07-22 克里蒂泰克公司 实体肿瘤治疗方法
CA3063420A1 (en) 2017-06-09 2018-12-13 Crititech, Inc. Treatment of epithelial cysts by intracystic injection of antineoplastic particles
AU2018284247B2 (en) 2017-06-14 2020-04-30 Crititech Inc. Methods for treating lung disorders
CA3076919A1 (en) 2017-10-03 2019-04-11 Crititech, Inc. Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer
WO2020061291A1 (en) * 2018-09-20 2020-03-26 Biovena Science, Llc Flutamide microsphere-based arterial embolization for treating prostate disorders
US11911499B2 (en) 2019-11-07 2024-02-27 Resurge Therapeutics, Inc. System and method for prostate treatment
US11338119B2 (en) * 2020-03-20 2022-05-24 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11344526B2 (en) * 2020-03-20 2022-05-31 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
CA3171976A1 (en) * 2020-03-20 2021-09-23 Carlos Schuler Implantable drug delivery devices for localized drug delivery
US11173291B2 (en) * 2020-03-20 2021-11-16 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11957654B2 (en) 2022-01-29 2024-04-16 Resurge Therapeutics, Inc. Treating benign prostatic hyperplasia
US11602516B1 (en) 2022-01-29 2023-03-14 Resurge Therapeutics Inc. Treating benign prostatic hyperplasia
EP4469108A1 (en) * 2022-01-29 2024-12-04 Resurge Therapeutics, Inc. Benign prostatic hyperplasia treatment system

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474813A (en) * 1980-10-24 1984-10-02 Schering Corporation Pharmaceutical preparations comprising flutamide
US5614206A (en) * 1995-03-07 1997-03-25 Wright Medical Technology, Inc. Controlled dissolution pellet containing calcium sulfate
US5795330A (en) 1996-10-10 1998-08-18 Etex Corporation Mixing device
CA2268156C (en) * 1996-10-16 2007-05-29 Etex Corporation Bioceramic compositions
US6391336B1 (en) 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
US5972384A (en) * 1997-10-01 1999-10-26 University Of Maryland, Baltimore Use of biologically active glass as a drug delivery system
CA2378486A1 (en) 1999-08-05 2001-02-15 Takashi Kurasawa Osteogenesis promoter sustained-release paste
US6497901B1 (en) * 2000-11-02 2002-12-24 Royer Biomedical, Inc. Resorbable matrices for delivery of bioactive compounds
US6645974B2 (en) * 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
US20030147936A1 (en) * 2002-02-07 2003-08-07 Velayudhan Sahadevan Prostatic hormonal implants treatment of prostate cancer
US8404681B2 (en) * 2003-03-24 2013-03-26 Luitpold Pharmaceuticals, Inc. Xanthones, thioxanthones and acridinones as DNA-PK inhibitors
GB0307082D0 (en) * 2003-03-27 2003-04-30 Gyne Ideas Ltd Drug delivery device and method
JP4927535B2 (ja) * 2003-04-03 2012-05-09 ジェシー エル エス オウ 腫瘍を標的指向化する薬物を封入した粒子
US20040224000A1 (en) * 2003-05-05 2004-11-11 Romano Deghenghi Implants for non-radioactive brachytherapy of hormonal-insensitive cancers
PL1680089T3 (pl) * 2003-10-22 2014-03-31 Lidds Ab Kompozycja zawierająca biodegradowalną ceramikę hydratującą do kontrolowanego dostarczania leków
KR20140014294A (ko) * 2005-03-31 2014-02-05 리드스 에이비 유효 물질의 국소 전달을 기본으로 하는 전립선 질병의 치료 방법

Also Published As

Publication number Publication date
EP1865924B1 (en) 2015-12-09
RU2007140243A (ru) 2009-05-10
US8936809B2 (en) 2015-01-20
JP2013067639A (ja) 2013-04-18
WO2006103112A3 (en) 2006-12-21
NO20075490L (no) 2008-01-02
AU2006228675B2 (en) 2012-05-17
KR20080002776A (ko) 2008-01-04
EP1865924A2 (en) 2007-12-19
WO2006103112A2 (en) 2006-10-05
ZA200708066B (en) 2016-07-27
CN101160116A (zh) 2008-04-09
US20080286205A1 (en) 2008-11-20
NO338679B1 (no) 2016-09-26
PL1865924T3 (pl) 2016-06-30
CN101160116B (zh) 2011-12-07
JP2008534546A (ja) 2008-08-28
HUE026158T2 (en) 2016-05-30
MX2007011908A (es) 2008-02-07
CA2602776C (en) 2013-10-22
JP5635231B2 (ja) 2014-12-03
RU2404747C2 (ru) 2010-11-27
CA2602776A1 (en) 2006-10-05
KR20140014294A (ko) 2014-02-05
ES2557988T3 (es) 2016-02-01
KR101380402B1 (ko) 2014-04-02
AU2006228675A1 (en) 2006-10-05
IL185690A0 (en) 2008-01-06

Similar Documents

Publication Publication Date Title
EP1865924B1 (en) Method for treating prostate diseases based on local delivery of active substances
JP6445123B2 (ja) 癌を治療するための方法及び組成物
JP2018522021A (ja) 治療用化合物の脳への一方向送達のためのインプラント組成物
KR20170045223A (ko) 국소 약물 전달을 위한 임플란트 및 이의 사용 방법
KR20090060306A (ko) 비타민 d 화합물 및 추가 치료제, 및 그를 함유하는 조성물을 투여하는 것을 포함하는, 암을 치료하는 방법
CN104519870A (zh) 可注射组合物
Lundgren Progestins in Breast Cancer Treatment: A Reveiw
AU2013308465A1 (en) Drug delivery systems and methods for treatment of prostate disease comprising gemicitabine
Jones et al. Use of DHEA in a patient with advanced prostate cancer: a case report and review
Brogden et al. Goserelin: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer
CN1168448C (zh) 预防和/或治疗乳腺癌的含类固醇芳香酶抑制剂的药物
Begg et al. Improvement of combined modality therapy with cisplatin and radiation using intratumoral drug administration in murine tumors
US20240016731A1 (en) Drug Implants Containing Apalutamide and Methods of Use Thereof
EP2152236B1 (en) Pharmaceutical composition of an anthracycline
JP2008538580A (ja) 活性ビタミンd化合物またはその模倣体による、化学療法または放射線療法と関連する肺疾患の治療、予防、および改善
US20250040935A1 (en) Fabrication of radiopaque resorbable hydrogel beads via microfluidics for catheter embolization applications
EP4308090A1 (en) Drug implants containing enzalutamide and methods of use thereof
TW201808266A (zh) 微小奈米化藥劑及其利用
Goya et al. Local injection of a sustained‐release antiandrogen formulation into a target prostatic site: an experimental study
Hussain et al. P115 A phase 2 multicenter study of the investigational single agent orteronel (ortl, TAK-700) in nonmetastatic castration-resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA)
Stevens et al. Medical Therapy for Meningiomas